Research sample repository for blood and cellular therapies

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This research sample repository aims to collect and provide access to blood samples for studies related to hematopoietic cell transplantation and other cellular therapies. It allows researchers to investigate factors affecting transplant outcomes, analyze genomic data, and study the distribution of HLA tissue types across populations. The repository will accept samples from donors, cord blood units, recipients of cellular therapies, and patients with marrow toxic injuries. This initiative supports anonymous research to enhance understanding and treatment of related conditions.

Why it matters

Who can join: the full rules

Eligibility to participate in the Research Sample Repository Protocol:

Hematopoietic Cell (HC) or Other Cellular Therapy Donors

* Donors are eligible to participate in the Research Sample Repository if they have donated or are scheduled to donate HCs or cellular therapy products to an allogeneic recipient either by a marrow harvest or by apheresis. This includes adults with and without decision making capacity and children.
* All donors registered on the National Marrow Donor Program (NMDP) Registry, regardless of whether they have been requested to donate a product for a patient, are eligible to participate in the Research Sample Repository.

Cord Blood Units (CBUs)

* Testable material from CBUs (Specimens) infused at treatment centers covered under the C. W. Bill Young Transplantation Program are eligible for inclusion in the Research Sample Repository. Material may be submitted by participating treatment centers, centralized laboratories and Cord Blood Banks.

Hematopoietic Cell Transplantation or Other Cellular Therapy Recipients

* All U.S. recipients of allogeneic or autologous HC transplants or cellular therapies are eligible to participate in the Research Sample Repository. This includes adults with and without decision making capacity and children.

Patients with Marrow Toxic Injury

* Any patient who is treated for a marrow toxic injury at a center participating in the NMDP's Radiation Injury Treatment Network (RITN) is eligible to participate in the Research Sample Repository. This includes adults with and without decision-making capacity and children.
* Eligible patients may have received support care only, growth factor support, hematopoietic stem cell transplant or other appropriate medical treatment for marrow toxic injury

Where it's running

• NMDP Biorepository
  New Brighton, Minnesota, United States Recruiting

Study contacts

• Principal investigator: Stephen Spellman — NMDP Be The Match/CIBMTR
• Study coordinator: Ashley Spahn
• Email: RepositoryIRB@NMDP.ORG

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comprehensive database for studying stem cell transplants and cellular therapies

  This study is creating a database to gather information on stem cell transplants and treatments to help improve recovery for patients and donors and make these therapies more accessible to everyone.

  Recruiting at 2 sites Center for International Blood and Marrow Transplant Research · Minneapolis, Minnesota and 1 other locations · NCT01166009

• See if 18F-FAPI-74 PET/CT can better detect fibrosis in heart and lung disease

  Researchers are testing a new PET/CT tracer, 18F-FAPI-74, to see if it can reveal early fibrotic changes in people with heart and lung diseases who are at risk for tissue scarring.

  Recruiting Phase 3 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07613099

• Allogeneic stem cell transplant with low-dose post-transplant cyclophosphamide to prevent graft-versus-host disease.

  This study tests whether giving low-dose (25 mg/kg) cyclophosphamide on days +3 and +4 after allogeneic peripheral blood stem cell transplant can prevent GVHD in adults with blood cancers who receive reduced-intensity or non-myeloablative conditioning.

  Recruiting Phase 2 Milton S. Hershey Medical Center · Hershey, Pennsylvania · NCT06926595

• Comparing two doses of olanzapine for preventing nausea in multiple myeloma patients receiving chemotherapy

  This study is testing whether two lower doses of olanzapine can help prevent nausea and vomiting in multiple myeloma patients receiving chemotherapy before a stem cell transplant.

  Recruiting Phase 3 Augusta University · Augusta, Georgia · NCT06588413

• Evaluating CMV Prophylaxis After Stem Cell Transplant

  This study is testing if a new test can help doctors decide how long to give a specific medicine to prevent a virus in patients who have had a stem cell transplant.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT06453460

• Personalized conditioning regimen for stem cell transplantation

  This study is testing a personalized treatment plan for stem cell transplants in people with blood cancers to see if adjusting the doses of certain medications can improve their outcomes.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT06028828

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.